H.B. Fuller stuns with $715M medical pivot — can the adhesives pure-play digest Advanced Medical Solutions?
FUL's surprise all-cash offer for AMS reshapes its portfolio toward higher-margin healthcare, but leverage jumps to ~4x and the stock is down 8% on the day.
FUL · Earnings Call · 2026-06-25
A strategic pivot into the operating room
On June 25, H.B. Fuller — a self-described pure-play adhesives company — announced a binding offer to acquire Advanced Medical Solutions (AMS) for GBP 2.85 per share, an enterprise value of ~£715M. The deal would nearly quintuple the size of its medical adhesives business, adding surgical adhesives, tapes, dressings, and formulated biosurgicals. “AMS is a highly compelling strategic fit and represents a rare opportunity to advance our long-term strategic priorities.” — Operator · 2026-06-25
The ambition is to create a fourth segment representing ~10% of combined revenue with expected EBITDA margins above 30% by 2030. The market reaction was skeptical — the stock dropped ~8% on the day, extending a 90-day drawdown to -9.5% and pushing the company's drawdown from its 2024 peak to -31.9%.
Management frames this as a natural evolution of the portfolio, not a departure. “We will continue to characterize ourself as a pure-play adhesive company... the majority of AMS's business is in adhesives and tapes.” — Operator · 2026-06-25 But the financial structure is aggressive: pro forma net leverage is expected to be ~4x, and the company only promises a return to its 2.5–3x target within two years. The cost synergy target of $55M — roughly 11–12% of AMS's revenue — is higher than any prior deal, a point management acknowledged while attributing it to public-company costs and the in-flight Peters Surgical integration.
It is higher than probably other deals we've done... the primary differences are two things: public company costs that exist within AMS... and the fact that the Peters Surgical synergies, which are well underway, are included.
Operating strength underneath the M&A headlines
Beyond the deal, the underlying business is performing well. Q2 organic revenue grew 2.6% (pricing +3%, volume slightly negative), adjusted EBITDA was up 9%, and EPS jumped 19%. The petrochemical supply chain disruption — driven by the Middle East conflict — has allowed Fuller to push through pricing actions and take share. On the call, Celeste Mastin noted:
“Our global sourcing capabilities and swift pricing actions have enabled us to maintain supply continuity and reliably serve our customers through this market disruption.” — Operator · 2026-06-25
But volumes are expected to decline mid-single digit in H2 as raw material costs stay elevated and consumer demand softens. This is a familiar tension from prior quarters; in the Q1 call (March 2026), management already warned that the pricing benefit would be offset by negative volume.“We are baking in additional price and raw material benefit, but also negative volume benefit.” — Operator, Conference Operator · 2026-03-26
The margin story remains intact: gross margin expanded 200bp year-on-year to 34.2%, driven by pricing and restructuring savings. The company's gross margin has trended from 30% in 2016 to ~31% last quarter, with clear improvement in the last three quarters.
The leverage bet
The real risk is balance sheet capacity. Effective net debt stood at -$2.0B, and interest coverage was 3.3x. The AMS acquisition adds ~$1B of committed financing, pushing pro forma leverage to ~4x. Management's de-leveraging path relies on $55M of synergies and strong cash generation, but the company has also guided to record Q2 cash flow ($121M) and full-year FCF of $300–325M. “We are confident in our ability to rapidly deleverage with a clear path to returning to our target range of 2.5 to 3 times within two years.” — Operator · 2026-06-25
Notably, the company ruled out divestitures to accelerate de-leveraging — a departure from its 2025 flooring divestiture. Strategic fit is the watchword, but investors will be watching the integration execution closely, especially given the formulated biosurgicals growth potential.
This is a genuine inflection point for FUL. The company is betting that its adhesive formulation expertise can unlock AMS's underpenetrated medical markets, but the leverage and integration risk are real. If the synergies materialize, Fuller emerges as a higher-margin, faster-growing specialty player; if not, the deleveraging story could take years.